

**Iris Grossman, Ph.D.**

**Vice President, Head of Personalized & Predictive Medicine, Analytics and Big Data, Teva**

Dr. Iris Grossman, VP, global head of the Personalized & Predictive Medicine, Analytics and Big Data (PPM-ABD) unit in Teva Global R&D, has dedicated her research career, in both industry and academia, to the advancement of the field of personalized medicine. Championing innovation, using biological and digital markers, together with analytic tools, she is currently charged with defining and implementing the global PPM-ABD strategy for Teva R&D. Teva is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Israel's leading financial magazine, Globes Magazine, selected Dr. Grossman as one of the country's top 40 professionals under 40 years of age in 2013.

Prior to joining Teva, Dr. Grossman was CEO and president of the pharmacogenetics management consultancy IsraGene Ltd., providing services to both the pharma and biotech sectors. This followed several years of spearheading pipeline pharmacogenetic programs for industry and academia as director of pharmacogenetics at Cabernet Pharmaceuticals Inc. Dr. Grossman moved into consultancy having been responsible for running large-scale pharmacogenetic programs at GlaxoSmithKline, with an emphasis on infectious and neurological diseases.

In academia, Dr. Grossman was a key member of Professor David Goldstein's team at the Center for Population Genomics and Pharmacogenetics, Institute for Genome Sciences and Policy, at Duke University. Dr. Grossman received her PhD from the Technion – Israel Institute of Technology, where her research project, conducted in collaboration with the Weizmann Institute for Science, investigated pharmacogenetic markers of multiple sclerosis treatment response.